In a population of cisgender men, transgender women, transgender men, and gender-nonbinary persons, the incidence of HIV is lower with receipt of twice-yearly subcutaneous lenacapavir.
El Mundo on MSN10h
Drug that protects against HIV with two 'shots' a year, discovery of the year for 'Science'Lenacapavir, a treatment administered subcutaneously every six months, is capable of preventing infection with very high ...
That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...
The drug lenacapavir, developed by Gilead Sciences, provides protection for half a year instead of one day and has performed extremely well in clinical trials.
The drug has been shown to be effective at preventing HIV infection but does not cure an existing HIV infection.
Dr. Greg Shay is a pediatric pulmonologist, a children's lung specialist, with the NGO MedGlobal who has just returned from a ...
The development of the HIV infection-preventing drug lenacapavir is the most important research development of 2024, Science ...
That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback